You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Accession NumberDB00271  (APRD00913)
TypeSmall Molecule

A commonly used x-ray contrast medium. As diatrizoate meglumine and as Diatrizoate sodium, it is used for gastrointestinal studies, angiography, and urography. [PubChem]

2,4,6-Triiodo-3,5-diacetamidobenzoic acidNot AvailableNot Available
3,5-Bis(acetylamino)-2,4,6-triiodobenzoic acidNot AvailableNot Available
3,5-diacetamido-2,4,6-triiodobenzoic acidNot AvailableNot Available
Acide amidotrizoiqueNot AvailableNot Available
Acidum amidotrizoicumNot AvailableNot Available
Acidum diacetylaminotrijodbenzoicumNot AvailableNot Available
AmidotrizoateNot AvailableNot Available
Amidotrizoic AcidNot AvailableNot Available
Amidotrizoic acid (anhydrous)Not AvailableNot Available
DiatrizoateNot AvailableNot Available
DiatrizoesaureNot AvailableNot Available
Diatrizoic acidNot AvailableNot Available
Diatrizoic acid (anhydrous)Not AvailableNot Available
Methalamic acidNot AvailableNot Available
TriombrinNot AvailableNot Available
Urografin acidNot AvailableNot Available
Urogranoic acidNot AvailableNot Available
External Identifiers Not Available
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Cystografininjection, solution300 mg/mLintravenousBRACCO DIAGNOSTICS INC1970-11-03Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Cystografin Diluteinjection, solution180 mg/mLintravesicalBRACCO DIAGNOSTICS INC1982-11-09Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Hypaque Oral Liquid - 50g/120mlliquid50 goral; rectalNycomed Imaging A.S.1997-03-171998-04-21Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Hypaque Oral Powderpowder997.4 mgoral; rectalGe Healthcare Canada Inc1998-02-192011-07-27Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Hypaque Oral Powder 0.9974g/gpowder997.4 mgoral; rectalSanofi Canada, Inc.1960-12-311997-07-30Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Hypaque Pwr 100%powder100 %oralSterling Winthrop Inc.1992-12-311996-09-10Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Hypaque Sodium 50% - Liq IVliquid50 %intravenousNycomed Imaging A.S.1998-04-222000-04-03Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Hypaque Sodium 50% Liqliquid50 %intravenousSterling Winthrop Inc.1991-12-311996-09-10Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Hypaque-m 18%solution18 %intravenous; cystographyAmersham Health Inc1997-08-272006-07-26Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Hypaque-m 18% Liqliquid18 %intravenous; cystographySanofi Canada, Inc.1979-12-311997-07-30Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Hypaque-m 30%solution30 %intravenous; cystographyAmersham Health Inc1998-01-162007-01-11Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Hypaque-m 30% Liqliquid30 %intravenous; cystographySanofi Canada, Inc.1969-12-311997-07-30Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Hypaque-m 60%solution60 %intravenous; cystography; arthographyAmersham Health Inc1997-04-162006-12-22Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Hypaque-m 60% Liqliquid60 %intravenous; cystography; arthographySanofi Canada, Inc.1968-12-311997-07-30Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Reno-60liquid600 mgintravenousBracco Imaging Canada1999-07-012010-01-05Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Reno-dipliquid30 %intravenousBracco Imaging Canada1998-07-202010-01-05Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Reno-m-60liquid600 mgintramuscular; intravenousSquibb Canada Inc., Division Of Bristol Myers Squibb Canada Inc.1976-12-311997-08-14Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Reno-m-dip Liq 30%liquid30 %intravenousSquibb Diagnostics, Division Of Bristol Myers Squibb Canada Inc.1981-12-311998-07-30Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Generic Prescription ProductsNot Available
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Hypaque Oral Liquid 50gm/120mlliquid50 goral; rectalSanofi Canada, Inc.1958-12-311997-07-30Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Hypaque Sodium Liq 50%liquid50 %intravenousSanofi Canada, Inc.1954-12-311997-07-30Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
International Brands
CardiografinNot Available
OdistonNot Available
Brand mixtures
Gastrografin - Liq OrlBracco Imaging Canada
Gastrografin LiqSquibb Diagnostics, Division Of Bristol Myers Squibb Canada Inc.
Hypaque-m 76%Amersham Health Inc
Hypaque-m 76% LiqSanofi Canada, Inc.
Hypaque-m Liq 76% USPSterling Winthrop Inc.
Md-60Tyco Healthcare
Md-76Tyco Healthcare
Md-76rMallinckrodt Inc.
Md-gastroviewMallinckrodt Inc.
Renocal-76Bracco Imaging Canada
Renografin-60 - Liq IVBracco Imaging Canada
Renografin-60 LiqSquibb Diagnostics, Division Of Bristol Myers Squibb Canada Inc.
Renografin-76 - Liq IVBracco Imaging Canada
Renografin-76 LiqSquibb Diagnostics, Division Of Bristol Myers Squibb Canada Inc.
Diatrizoate meglumine
  • Monoisotopic Mass: 808.880309705
  • Average Mass: 809.1272
Diatrizoate sodium
  • Monoisotopic Mass: 635.751581689
  • Average Mass: 635.8954
CAS number117-96-4
WeightAverage: 613.9136
Monoisotopic: 613.769637046
Chemical FormulaC11H9I3N2O4
3,5-diacetamido-2,4,6-triiodobenzoic acid
DescriptionThis compound belongs to the class of organic compounds known as aminobenzoic acids. These are benzoic acids containing an amine group attached to the benzene moiety.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassBenzoic acids and derivatives
Direct ParentAminobenzoic acids
Alternative Parents
  • N-arylamide
  • Halobenzoic acid
  • 4-halobenzoic acid
  • 2-halobenzoic acid
  • Halobenzoic acid or derivatives
  • 4-halobenzoic acid or derivatives
  • 2-halobenzoic acid or derivatives
  • Acetanilide
  • Aminobenzoic acid
  • Benzoic acid
  • Benzoyl
  • Iodobenzene
  • Halobenzene
  • Aryl iodide
  • Aryl halide
  • Acetamide
  • Vinylogous halide
  • Secondary carboxylic acid amide
  • Carboxamide group
  • Monocarboxylic acid or derivatives
  • Carboxylic acid
  • Carboxylic acid derivative
  • Carboxylic acid amide
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Organoiodide
  • Organohalogen compound
  • Carbonyl group
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External Descriptors
IndicationUsed, alone or in combination, for a wide variety of diagnostic imaging methods, including angiography, urography, cholangiography, computed tomography, hysterosalpingography, and retrograde pyelography. It can be used for imaging the gastrointestinal tract in patients allergic to barium.
PharmacodynamicsDiatrizoate is the most commonly used water-soluble, iodinated, radiopaque x-ray contrast medium. Radiopaque agents are drugs used to help diagnose certain medical problems. They contain iodine, which blocks x-rays. Depending on how the radiopaque agent is given, it localizes or builds up in certain areas of the body. The resulting high level of iodine allows the x-rays to make a "picture" of the area. The areas of the body in which the radiopaque agent localizes will appear white on the x-ray film. This creates the needed distinction, or contrast, between one organ and other tissues. The contrast will help the doctor see any special conditions that may exist in that organ or part of the body.
Mechanism of actionDiatrizoate is an iodine-containing X-ray contrast agent. Iodated contrast agents were among the first contrast agents developed. Iodine is known to be particular electron-dense and to effectively scatter or stop X-rays. A good contrast agent requires a high density of electron-dense atoms. Therefore, the more iodine, the more "dense" the x-ray effect. Iodine based contrast media are water soluble and harmless to the body. These contrast agents are sold as clear colorless water solutions, the concentration is usually expressed as mg I/ml. Modern iodinated contrast agents can be used almost anywhere in the body. Most often they are used intravenously, but for various purposes they can also be used intraarterially, intrathecally (the spine) and intraabdominally - just about any body cavity or potential space.
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationHowever, it is not metabolized but excreted unchanged in the urine, each diatrizoate molecule remaining "obligated" to its sodium moiety. The liver and small intestine provide the major alternate route of excretion for diatrizoate. Injectable radiopaque diagnostic agents are excreted unchanged in human milk. Saliva is a minor secretory pathway for injectable radiopaque diagnostic agents.
Half lifeNot Available
ClearanceNot Available
ToxicityHigh osmolal radiocontrast agents like diatrizoate are cytotoxic to renal cells. The toxic effects include apoptosis, cellular energy failure, disruption of calcium homeostasis, and disturbance of tubular cell polarity, and are thought to be linked to oxidative stress.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Predicted ADMET features
Human Intestinal Absorption-0.8406
Blood Brain Barrier+0.9152
Caco-2 permeable+0.5151
P-glycoprotein substrateNon-substrate0.7998
P-glycoprotein inhibitor INon-inhibitor0.9476
P-glycoprotein inhibitor IINon-inhibitor0.9752
Renal organic cation transporterNon-inhibitor0.9705
CYP450 2C9 substrateNon-substrate0.7632
CYP450 2D6 substrateNon-substrate0.8853
CYP450 3A4 substrateNon-substrate0.6258
CYP450 1A2 substrateNon-inhibitor0.73
CYP450 2C9 inhibitorNon-inhibitor0.8696
CYP450 2D6 inhibitorNon-inhibitor0.94
CYP450 2C19 inhibitorNon-inhibitor0.9271
CYP450 3A4 inhibitorNon-inhibitor0.9376
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9268
Ames testAMES toxic0.508
BiodegradationNot ready biodegradable0.9832
Rat acute toxicity1.9136 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9975
hERG inhibition (predictor II)Non-inhibitor0.9623
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
  • Bayer healthcare pharmaceuticals inc
  • Bracco diagnostics inc
  • Ge healthcare
  • Mallinckrodt inc
  • Mallinckrodt medical inc
  • Isotex diagnostics
Dosage forms
Injection, solutionintravenous300 mg/mL
Injection, solutionintravesical180 mg/mL
Liquidoral; rectal660; 100 mg/mL; mg/mL
Solutionoral66 %
Liquidoral; refer (see dosage form)66 %
Liquidoral; rectal50 g
Powderoral; rectal997.4 mg
Powderoral100 %
Liquidintravenous50 %
Solutionintravenous; cystography18 %
Liquidintravenous; cystography18 %
Solutionintravenous; cystography30 %
Liquidintravenous; cystography30 %
Solutionintravenous; cystography; arthography60 %
Liquidintravenous; cystography; arthography60 %
Solutionintra-arterial; intravenous66 %
Liquidintra-arterial; intravenous66 %
Liquidintravenous66 %
Solutionintra-arterial; intravenous520 mg
Solutionintra-arterial; intravenous660 mg
Solutionintravenous660; 100 mg/mL; mg/mL
Solutionoral; rectal600; 100 mg/mL; mg/mL
Liquidintravenous600 mg
Liquidintramuscular; intravenous600 mg
Liquidintravenous30 %
Liquidintravenous52 %
Injection, solutionintrauterine527; 268 mg/mL; mg/mL
Unit descriptionCostUnit
Gastrografin 66-10 solution0.92USD ml
Hypaque sodium oral powder0.68USD g
Conray 60% vial0.36USD ml
Cystografin 30% infus. btl0.22USD ml
Conray-43 vial0.2USD ml
Conray-30 infusion bottle0.16USD ml
Hypaque 41.66% liquid0.16USD ml
Cystografin-dilute 18% btl0.13USD ml
Cysto-conray 17.2% vial0.11USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Experimental Properties
melting point>250Larsen, A.A.; US. Patent 3,076,024; January 29, 1963; assigned to Sterling Drug,Inc.
logP3.3Not Available
Predicted Properties
Water Solubility0.107 mg/mLALOGPS
pKa (Strongest Acidic)2.17ChemAxon
pKa (Strongest Basic)-4.2ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area95.5 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity103.13 m3·mol-1ChemAxon
Polarizability38.43 Å3ChemAxon
Number of Rings1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Mass Spec (NIST)Not Available
SpectraNot Available
Synthesis Reference

Larsen, A.A.; US. Patent 3,076,024; January 29, 1963; assigned to Sterling Drug,Inc.

General ReferencesNot Available
External Links
ATC CodesV08AA01
AHFS Codes
  • 36:68.00
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (73.2 KB)
Drug Interactions
AldesleukinMay enhance the potential for allergic or hypersensitivity reactions to Iodinated Contrast Agents.
Food InteractionsNot Available
comments powered by Disqus
Drug created on June 13, 2005 07:24 /Updated on April 11, 2014 10:53